Back | Next |
home / stock / avir / avir message board
Subject | By | Source | When |
---|---|---|---|
$AVIR short squeeze all day | crudeoil24 | investorshub | 04/27/2023 12:06:26 PM |
$AVIR Price trading | Wallst_junkie | investorshub | 04/26/2023 9:54:59 AM |
The trading | Mikey | investorshub | 04/26/2023 5:08:45 AM |
should we be shorting? | rosemountbomber | investorshub | 04/26/2023 3:19:17 AM |
$AVIR MomentumIts trading last trade up | DewDiligence | investorshub | 04/23/2023 3:45:51 PM |
Looks pretty positive | DewDiligence | investorshub | 04/22/2023 2:43:32 AM |
$AVIR reports final data from phase-2 COVID trial: | DewDiligence | investorshub | 04/12/2023 5:06:57 PM |
$AVIR 4Q22 CC transcript: | DewDiligence | investorshub | 03/03/2023 5:40:37 PM |
$AVIR 4Q22 results12/31/22 cash=$647M: | DewDiligence | investorshub | 02/28/2023 9:25:11 PM |
$AVIR$ JPM webcast slides: | DewDiligence | investorshub | 01/11/2023 11:11:26 PM |
$AVIR 2023 newsflow: | DewDiligence | investorshub | 01/09/2023 5:21:24 PM |
AVIR 3Q22 results9/30/22 cash=$665M: | DewDiligence | investorshub | 11/07/2022 11:08:19 PM |
AVIR 2Q22 results6/30/22 cash=$684.5M (down from $705.5M at 3/31/22): | DewDiligence | investorshub | 08/08/2022 8:30:31 PM |
AVIR 3/31/22 cash=$705.5Mburning $58.9M in 1Q22... | DewDiligence | investorshub | 05/10/2022 4:32:29 PM |
LOL re $AVIRs attempt to be relevant: | DewDiligence | investorshub | 12/15/2021 12:47:23 AM |
$AVIR - Friday Rundown, Monday Expectations | Jake L | investorshub | 10/31/2021 10:18:56 PM |
Watching for a uptrend | Wallst_junkie | investorshub | 10/20/2021 2:08:37 PM |
GOOD$ JOB!!! ya, by the time I | dealerschool2006 | investorshub | 10/20/2021 1:06:23 PM |
Wow! That's why you don't hold these Pharma | crudeoil24 | investorshub | 10/20/2021 2:08:50 AM |
wow went sub $11 and traded the whole | TheFinalCD | investorshub | 10/20/2021 2:05:48 AM |
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...
BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live...
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged i...